CD8A and neoplasm: For helper T cells that exert their antitumor effects indirectly through the production of effector cytokines, by helping to prime CD8+ T cells, or by activating myeloid-derived cells, MHC-II neoantigen presentation on tumor cells would not be mandatory, and in fact many tumor cells of epithelial origin lack surface MHC-II expression (24–26).